Though the definitive diagnosis of the celiac disease is based in characteristic histological changes observed in intestinal biopsies, the serological tests, such as the detection of antibodies anti-gliadins, anti-tTG and anti-endomysium, represent methods of analyses cheaper and less invasive to the detection of the disease.
According to John Kernohan, Director of York Nutritional Laboratories, This new rapid test is a great improvement over our original cdSCAN, which we introduced back in 2002. Individuals now have a even quicker, more convenient and reliable means to determine if Celiac Disease or gluten intolerance is the culprit behind their ill-health.
The new and improved cdSCAN is able to analyze a tiny sample of whole blood, serum or plasma for IgA/IgG/IgM antibodies against human Tissue Transglutaminase (tTG) and IgA antibodies against gliadin. The kit can be utilized in either the comfort of ones own home or at a doctors office, and the results are available in approximately 10 minutes.
In addition to the approximate 1 million Americans suffering from classical Celiac Disease, there are an equal number of individuals with silent or latent Celiac Disease who are unaware of their condition because they do not have the signs and symptoms typically associated with celiac disease. These individuals run the risk of developing full-blown celiac disease later in life and complications
such as bowel cancer, infertility and autoimmune diseases, making proper and early diagnosis very important.
Information about the cdSCAN is available from York Nutritional Laboratories, Inc. Please contact John Kernohan at (888) 751-3388.